 |
Previous Article | Next Article 
The Journal of Neuroscience, May 15, 1999, 19(10):3674-3680
Region-Specific Regulation of RGS4 (Regulator of
G-Protein-Signaling Protein Type 4) in Brain by Stress and
Glucocorticoids: In Vivo and In Vitro
Studies
Yan G.
Ni,
Stephen J.
Gold,
Philip A.
Iredale,
Rose Z.
Terwilliger,
Ronald S.
Duman, and
Eric J.
Nestler
Laboratory of Molecular Psychiatry and Departments of Psychiatry
and Neurobiology, Yale University School of Medicine, New Haven,
Connecticut 06508
 |
ABSTRACT |
The present study demonstrates that the regulator of
G-protein-signaling protein type 4 (RGS4) is differentially regulated in the locus coeruleus (LC) and the paraventricular nucleus
(PVN) of the hypothalamus by chronic stress and glucocorticoid
treatments. Acute or chronic administration of corticosterone to adult
rats decreased RGS4 mRNA levels in the PVN but increased these levels in the LC. Similarly, chronic unpredictable stress decreased RGS4 mRNA
levels in the PVN but had a strong trend to increase these levels in
the LC. Chronic stress also decreased RGS4 mRNA levels in the
pituitary. The molecular mechanisms of RGS4 mRNA regulation were
further investigated in vitro in the LC-like CATH.a cell line and the neuroendocrine AtT20 cell line using the synthetic corticosterone analog dexamethasone. Consistent with the findings in vivo, dexamethasone treatment caused a dose- and
time-dependent decrease in RGS4 mRNA levels in AtT20 cells but a dose-
and time-dependent increase in CATH.a cells. RGS4 mRNA regulation seen
in these two cell lines seems to be attributable, at least in part, to
opposite changes in mRNA stability. The differential regulation of RGS4 expression in the LC and in key relays of the
hypothalamic-pituitary-adrenal axis could contribute to the brain's
region-specific and long-term adaptations to stress.
Key words:
RGS proteins; glucocorticoids; chronic stress; locus
coeruleus; paraventricular nucleus of the hypothalamus; HPA
(hypothalamic-pituitary-adrenal) axis; CATH.a cells; AtT20 cells; cAMP pathway
 |
INTRODUCTION |
The recently discovered regulators
of G-protein-signaling (RGS) proteins negatively modulate G-protein
function by accelerating the GTPase activity of G-protein subunits.
There has been intense interest in the function of RGS proteins, in
particular, in their interaction with G-proteins. Several members of
the RGS family inhibit G i, G o, G q, G z, or transducin
(G t) subunits but not G s or G 12 (Berman et al., 1996 ; Hunt et
al., 1996 ; Watson et al., 1996 ; Hepler et al., 1997 ; Wieland et al.,
1997 ). Because of its apparently exclusive expression in brain, RGS
protein type 4 (RGS4) has received a wealth of attention. Experiments
with purified recombinant proteins in vitro and with stably
transfected mammalian cells show that RGS4 attenuates G i- and
G q-mediated signaling by acting as a GTPase-activating protein
(Hepler et al., 1997 ; Huang et al., 1997 ). On the basis of the
crystal structure of RGS4 bound to
AlF4 -activated G i, it has been
suggested that RGS4 accelerates the GTPase activity of G i and G q
by stabilizing the subunit's transition state for GTP hydrolysis
(Tesmer et al., 1997 ).
We have characterized previously the distribution of mRNAs encoding
RGS3-RGS11 in rat brain (Gold et al., 1997 ). Of these RGS proteins,
RGS4 mRNA is relatively abundant in many brain regions, including
several structures of the stress response circuitry, such as the
cerebral cortex, amygdala, thalamus, paraventricular nucleus (PVN) of
the hypothalamus, and locus coeruleus (LC). Although a recent study has
shown changes in several RGS mRNAs after acute amphetamine treatment
(Burchett et al., 1998 ), overall, little is known regarding the
physiological consequences of altered RGS protein expression.
One functional consequence of RGS4 regulation could be modulation of
signaling via the cAMP pathway. Thus, a decrease in RGS4 expression, by
enhancing G i-mediated signaling, could result in diminished adenylyl
cyclase activity. There is strong evidence that regulation of the cAMP
pathway plays an important role in stress responses. For instance,
corticotropin-releasing factor (CRF), the primary neurotransmitter
controlling activity of the hypothalamic-pituitary-adrenal (HPA)
axis, acts by stimulating adenylyl cyclase (Labrie et al., 1982 ; Litvin
et al., 1984 ; Battaglia et al., 1987 ). Adrenal glucocorticoid, a key
hormone of the stress response, exerts negative feedback control over
the HPA axis by inhibiting CRF secretion by the PVN and
adrenocorticotropic hormone (ACTH) secretion by the pituitary. These
actions oppose the cAMP pathway, which is known to promote the
synthesis and release of CRF and of ACTH in these tissues (Giguere et
al., 1982 ; Labrie et al., 1982 ; Keller and Dallman, 1984 ; Litvin et
al., 1984 ; Dorin et al., 1993 ). In contrast, chronic stress induces
upregulation of several components of the cAMP pathway, including
protein kinase A and adenylyl cyclase, in the LC (Melia et al., 1992 ),
a brain region thought to mediate certain attentional and autonomic
features of the stress response.
The goal of the present study was to investigate directly the effect of
chronic stress and corticosterone treatments on RGS4 expression in
brain regions associated with the stress response and to gain insight
into the possible mechanisms involved by analyzing RGS4 expression in
two cell lines in vitro. We show that chronic stress or
glucocorticoid treatment decreases RGS4 mRNA levels in the PVN and
pituitary but increases RGS4 mRNA levels in the LC. Decreased RGS4
expression in the PVN and pituitary, by potentiating G i function,
could contribute to stress- and glucocorticoid-induced negative
feedback of these brain regions. Conversely, increased RGS4 expression
in the LC, by diminishing G i function, is consistent with an
upregulation of the cAMP pathway known to occur in this brain region
after chronic stress.
 |
MATERIALS AND METHODS |
Animal treatments. Adult male Sprague Dawley rats
(initial weight, 190-240 gm; Charles River Laboratories, Wilmington,
MA) were used in this study. Rats were caged in groups of two
with food and water available ad libitum in a 12 hr
light/dark cycle (lights off at 7 P.M.). All rats were received from
the vendor several days before initiating various treatments to
habituate them to our vivarium. In the acute corticosterone treatment,
rats received a single injection of either corticosterone (40 mg/kg in
sesame oil, s.c.; Sigma, St. Louis, MO) or vehicle and were used 6 hr
later, at which time elevated plasma corticosterone levels have been
documented (Pavlides et al., 1993 ). In the chronic corticosterone
treatment, rats were implanted with sustained-release pellets (100 mg;
7 d release; Innovative Research of America, Toledo, OH) and used
7 d later as described (Ortiz et al., 1995 ). The control group
received sham surgery. Chronic unpredictable stress, which involves
animals being exposed to two of eight different stressors per day for
10 d, was administered exactly according to published procedures
(Ortiz et al., 1996 ).
Cell culture. AtT20 cells (purchased from American Type
Culture Collection, Rockville, MD) were cultured in DMEM containing 10% fetal bovine serum. CATH.a cells were obtained from Dr. D. M. Chikaraishi (Duke University, Durham, NC) and were cultured in RPMI
1640 medium containing 4% fetal bovine serum and 8% horse serum.
Initial experiments were also performed on SH-SY5Y neuroblastoma cells
(a generous gift of Dr. S. Brene, Karolinska Institute) and C6 glioma
cells (purchased from American Type Culture Collection), which were
cultured similarly as the AtT20 cells. Cells were split at a ratio of
1:5 or 1:10 every 4-5 d. Cells were treated with dexamethasone (in
ethanol; Sigma) at the indicated concentrations for 4 hr unless
otherwise stated. mRNA stability was assayed using the transcription
inhibitor actinomycin D (2 µg/ml; Calbiochem, La Jolla, CA). The
effect of CRF or forskolin was tested by incubating the cells with CRF
(100 nM; a generous gift of Dr. J. River, Salk Institute,
La Jolla, CA) or forskolin (5 µM, in ethanol; Sigma) for
4 hr. Treatments were terminated at the indicated times by addition of
an ice-cold guanidinium thiocyanate lysis buffer from the RNAqueous kit
(Ambion, Austin, TX). Cell lysates were harvested for RNA extraction
(see below).
Riboprobes. RGS4 templates were generated by
HindIII digestion of pMK152 (obtained from Dr. M. Koelle,
Yale University, New Haven, CT) (Koelle and Horvitz, 1996 ). Cyclophilin
templates (pTRI-cyclophilin-mouse) were purchased from Ambion.
Antisense riboprobes for RGS4 or cyclophilin were transcribed with T3
RNA polymerase (Boehringer Mannheim, Indianapolis, IN) in the presence
of [32P]CTP (Northern blot analysis) or
35S-UTP (in situ hybridization) (Dupont NEN,
Boston, MA). Riboprobes for Northern analysis were purified with Nuc
Trap minicolumns (Stratagene, La Jolla, CA). Riboprobes for in
situ hybridization were purified by phenol-chloroform extraction
followed by ethanol precipitation on dry ice with 2.5 M
ammonium acetate.
Northern blot analysis. RNA was prepared using RNAqueous
kits (Ambion) and following the manufacturer's protocol. The
concentration of RNA was determined by spectrophotometry. Samples of 25 µg of RNA were electrophoresed through a formaldehyde-1.2% agarose
gel containing ethidium bromide, transferred to Nitropure-supported nitrocellulose (MSI, Westboro, MA) by capillary blotting, and UV
cross-linked to the membrane (Stratalinker; Stratagene). Northern blots
were hybridized for 18 hr at 65°C in a roller tube oven in
hybridization buffer containing 50% deionized formamide, 4× SSC, 20 mM Tris-HCl, pH 7.5, 0.1% SDS, 1× Denhardt's solution, 10% dextran sulfate, 100 µg/ml denatured salmon sperm DNA, and 2 × 106 cpm/ml (RGS4) or 2 × 105 cpm/ml (cyclophilin) 32P-labeled
riboprobes. Blots were washed at 65°C for 20 min in the following
buffers: twice in 2× SSC and 0.1% SDS, once in 0.5× SSC and 0.1%
SDS, and once in 0.1× SSC and 0.1% SDS. The blots were visualized and
quantified by image analysis (Molecular Imager System GS-363; Bio-Rad,
Hercules, CA). RGS4 mRNA levels were normalized to cyclophilin levels
to control for variations in gel loading and RNA transfer.
In situ hybridization. In situ
hybridization of brain sections was conducted either on free-floating
sections (Gall et al., 1995 ) or on slide-mounted sections (Vaidya et
al., 1997 ). The two methods yielded equivalent results. In the
free-floating hybridizations, rats were perfused transcardially with 50 ml of saline followed by 400 ml of 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. Brains were post-fixed,
cryoprotected, and then sectioned at 30 µm in the coronal plane with
a microtome. Serial sections between 0.68 and 1.04 mm bregma, which
includes the large majority of the locus coeruleus (Paxinos and Watson,
1982 ), were analyzed for this nucleus. In the slide hybridizations,
brains were fresh frozen and then sectioned at 14 µm in the coronal
plane with a cryostat. The pituitary was analyzed with the slide
hybridization method. Transverse pituitary sections (14 µm) were
mounted on UltraStick slides (Becton Dickinson, Rutherford, NJ).
RNA-labeling densities were determined by densitizing autoradiographic
film using Image analysis software (NIH Image) as described previously (Gold et al., 1997 ). For high resolution analysis, sections were dipped
in autoradiographic emulsion (NTB2; Eastman Kodak, Rochester, NY),
exposed for 8 weeks, developed with D19 (Eastman Kodak), fixed with
Kodak fixer, counterstained with cresyl violet, and coverslipped with
DPX (Aldrich, Milwaukee, WI).
 |
RESULTS |
Regulation of RGS4 mRNA by chronic unpredictable stress
In initial studies, we examined the effect of chronic (10 d)
unpredictable stress on the levels of RGS4 mRNA in rat brain by
in situ hybridization. Of the many brain regions that
express high levels of RGS4 (see Gold et al., 1997 ), the PVN and LC
showed the most apparent effects of stress (Figs.
1, 2). In
the PVN, chronic stress caused a 28% decrease in RGS4 mRNA levels
(p < 0.05, two-tailed Student's t
test) (Fig.
1A,B,G-I). In
contrast, in the LC, there was a strong trend for increased (21%) RGS4
mRNA levels after chronic stress (p < 0.079)
(Fig. 2A,B,G). Chronic stress had no marked effect in the thalamus or cerebral cortex, brain
regions that also express high levels of RGS4 mRNA, or in the
hippocampus, which expresses RGS4 mRNA at a very low level.

View larger version (74K):
[in this window]
[in a new window]
|
Figure 1.
A-H, Bright-field film
(A-F) and dark-field emulsion (G,
H) autoradiograms of RGS4 expression in the PVN
of control rats (A, C, E,
G) or those treated with chronic stress
(B, H; chr stress), acute
corticosterone (D; ac cort), or chronic
corticosterone (F; chr cort).
cp, Striatum; ctx, cortex;
hp, hippocampus; pvn, paraventricular
nucleus of the hypothalamus; th, thalamus. Scale bar:
A-F, 3.3 mm; G, H, 1.2 mm. I, Summary of results (mean ± SEM;
n = 3-6; *p < 0.05, two-tailed t test).
|
|

View larger version (71K):
[in this window]
[in a new window]
|
Figure 2.
A-F, Film autoradiograms of RGS4
mRNA expression in the LC of control rats (A,
C, E) or those treated with chronic
stress (B; chr stress), acute
corticosterone (D; ac cort), or chronic
corticosterone (F; chr cort).
lc, Locus coeruleus. G, Summary of
results (mean ± SEM; n = 6;
*p < 0.05, two-tailed t
test).
|
|
As shown in Figure 3, RGS4 mRNA was
expressed at a relatively high level in the anterior and intermediate
lobe of the pituitary. Interestingly, chronic stress decreased levels
of RGS4 mRNA in both parts of the pituitary, with the most prominent
effect in the intermediate lobe (49% decrease; p < 0.01) (Fig. 3).

View larger version (103K):
[in this window]
[in a new window]
|
Figure 3.
Film autoradiograms of RGS4 mRNA expression in the
pituitary of control (A) and chronic
stress-treated (B) rats. Results shown are
representative of the analysis of six rats in each treatment group.
al, Anterior lobe; il, intermediate lobe;
nl, neural lobe (posterior lobe).
|
|
Regulation of RGS4 mRNA by corticosterone treatments
We next studied the ability of glucocorticoids to mimic the
effects of stress on RGS4 expression by examining the effect of acute
and chronic corticosterone treatment on RGS4 mRNA levels in rat brain.
In the PVN there was a 22% (p < 0.05) and 27%
(p < 0.01) decrease in RGS4 mRNA levels after
acute and chronic corticosterone treatment, respectively (Fig.
1C-F,I). In contrast, in the LC there was
a 35% (p < 0.05) and 46%
(p < 0.05) increase in RGS4 mRNA levels after
acute and chronic corticosterone treatment, respectively (Fig.
2C-G). Acute and chronic corticosterone treatment had no
discernible effect on the levels of RGS4 mRNA in other brain regions
(Figs. 1, 2), except for the cingulate cortex where chronic treatment
tended to decrease RGS4 expression (14%; p < 0.065).
Regulation of RGS4 mRNA by dexamethasone in vitro
To establish an in vitro model system with which to
investigate further the regulation of RGS4 mRNA, we screened several
cell lines for RGS4 mRNA expression. RGS4 mRNA was expressed in most of
the cell lines examined, including CATH.a, AtT20, SH-SY5Y
neuroblastoma, and U373 astrocytoma cells, but not in C6 glioma cells.
Moreover, these initial studies showed that RGS4 mRNA levels were
downregulated in CATH.a cells after a 4 hr CRF (100 nM)
treatment, as well as in AtT20 cells after a 4 hr dexamethasone (0.2 µM) treatment (data not shown). CATH.a cells were derived
from a brainstem tumor of a tyrosine hydroxylase-simian virus 40 T
antigen transgenic mouse and resemble in many respects noradrenergic
neurons of the LC (Suri et al., 1993 ; Widnell et al., 1994 ). AtT20
cells were derived from mouse pituitary and exhibit many properties of
pituitary corticotrophs (ACTH-secreting cells). This cell line has long been used in studying stress mechanisms, particularly, the feedback inhibition by glucocorticoids on CRF and ACTH. Therefore, we decided to
characterize further the regulation of RGS4 mRNA by the potent synthetic glucocorticoid dexamethasone in these two cell lines.
CATH.a cells
Dexamethasone induced a dose-dependent increase in RGS4 mRNA
levels in CATH.a cells as determined by Northern blotting (Fig. 4A). The effect of
dexamethasone was detectable at subnanomolar concentrations, with an
EC50 value of ~37 nM. In addition, the upregulation of RGS4 mRNA levels occurred in a time-dependent manner
(Fig. 5A). When 0.2 µM dexamethasone was used (Fig. 5A), the
effect was significant within 4 hr. By 24 hr, levels of RGS4 mRNA were
almost 200% that of controls. Longer incubations with dexamethasone
(>24 hr) had diminished effects on RGS4 expression. However, even
after 72 hr of dexamethasone exposure, increased levels of RGS4 mRNA
persisted (~50% increase; data not shown). Similar increases in RGS4
mRNA levels were seen with corticosterone itself (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
Figure 4.
Dose-response analyses for dexamethasone
(Dex) regulation of RGS4 mRNA expression in CATH.a
(A) and AtT20 (B) cells.
Data are expressed as the mean percent of control (± SEM;
n = 3-6; *p < 0.05, two-tailed t test). Con, Control.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Figure 5.
Time course study for dexamethasone regulation of
RGS4 mRNA expression in CATH.a (A) and AtT20
(B) cells. Data are expressed as the mean percent
of control (± SEM; n = 3-6;
*p < 0.05, two-tailed t
test).
|
|
To characterize the molecular mechanism underlying the upregulation of
RGS4 expression in CATH.a cells by dexamethasone, we examined the
effect of dexamethasone on RGS4 mRNA stability. Cells were incubated
with 200 nM dexamethasone for 1 hr, followed by addition of
the transcription inhibitor actinomycin D. Exposure to dexamethasone
increased the half-life of RGS4 mRNA from 2.6 ± 0.1 to 4.0 ± 0.03 hr (mean ± SEM; n = 4) (Fig.
6A). This finding indicates that the dexamethasone-induced upregulation of RGS4 mRNA in
CATH.a cells could be attributable, at least in part, to an increase in
the stability of the mRNA.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 6.
Effect of actinomycin D on dexamethasone
regulation of RGS4 mRNA expression in CATH.a (A)
and AtT20 (B) cells. Data are expressed as the
mean percent of control (± SEM; n = 4).
|
|
As mentioned above, in our initial experiments we detected a
downregulation of RGS4 mRNA by CRF in CATH.a cells, an effect opposite
to that seen with dexamethasone. Because CRF acts by stimulating
adenylyl cyclase, it was of interest to determine whether forskolin,
which directly activates the catalytic moiety of adenylyl cyclase,
exerts a similar effect on RGS4 expression. Indeed, application of CRF
(100 nM) or forskolin (5 µM) for 4 hr caused
a 28 or 36% decrease in RGS4 mRNA levels, respectively (p < 0.05) (Fig.
7A).

View larger version (44K):
[in this window]
[in a new window]
|
Figure 7.
Comparison of the regulation of RGS4 mRNA
expression in CATH.a (A) and AtT20
(B) cells by dexamethasone (Dex),
CRF, and forskolin (FK). Data are expressed as
the mean percent of control (± SEM; n = 4;
*p < 0.05, two-tailed t
test).
|
|
AtT20 cells
In contrast to the upregulation of RGS4 mRNA expression seen in
CATH.a cells, a dose-dependent downregulation of RGS4 mRNA was caused
by dexamethasone treatment in AtT20 cells (Fig. 4B). The effect of dexamethasone was detectable at subnanomolar
concentrations, with an EC50 value of ~0.3
nM. Maximal effects of dexamethasone (close to a 50%
inhibition) were seen at ~20 nM. In addition, the
downregulation of RGS4 mRNA levels in AtT20 cells was time-dependent. When 200 nM dexamethasone was applied, the effect was
significant within 1 hr and peaked between 2 and 6 hr of treatment
(Fig. 5B). At later time points, RGS4 mRNA levels partially
recovered, even though dexamethasone was still present, but remained
significantly suppressed after 50 hr.
A possible role for mRNA stability in dexamethasone regulation of RGS4
mRNA levels was also studied in AtT20 cells using actinomycin D. Exposure to dexamethasone significantly decreased the half-life of RGS4
mRNA from 6.2 ± 0.1 to 3.4 ± 0.1 hr (mean ± SEM;
n = 3) (Fig. 6B). This finding is
consistent with the possibility that the dexamethasone-induced
downregulation of RGS4 mRNA in AtT20 cells may result, at least in
part, from a decrease in mRNA stability.
Finally, we studied the effect of CRF and forskolin on RGS4 expression
in AtT20 cells. In contrast to the results seen in CATH.a cells,
application of CRF or forskolin did not produce any detectable change
in RGS4 mRNA levels in AtT20 cells (Fig. 7B).
 |
DISCUSSION |
The present study demonstrates that expression of RGS4 mRNA is
differentially regulated in the LC versus the PVN and pituitary by
chronic stress and glucocorticoid treatments. In the LC, levels of RGS4
mRNA were significantly increased by acute and chronic corticosterone
treatment, and there was a strong trend for an increase after chronic
unpredictable stress. In contrast, in the PVN, levels of RGS4 mRNA were
decreased by acute and chronic corticosterone treatment and by chronic
stress. Similar decreases were seen in the anterior and intermediate
lobe of the pituitary after chronic stress. To understand the molecular
mechanisms underlying these changes, we studied the regulation of RGS4
mRNA by dexamethasone in the LC-like CATH.a cell line and the
neuroendocrine AtT20 cell line. In CATH.a cells, levels of RGS4 mRNA
were dose-dependently increased by dexamethasone, whereas, in AtT20
cells, levels of RGS4 mRNA were dose-dependently decreased by
dexamethasone. Further studies showed that the opposite effects of
dexamethasone on RGS4 expression in the two cell lines could be
explained, at least in part, by opposite changes in the stability of
RGS4 mRNA.
Previous studies have shown that the LC, which is the major
noradrenergic nucleus in the brain, responds to stress with several adaptations. Acute or chronic stress increases the spontaneous firing
rate of LC neurons (Abercrombie and Jacobs, 1987 ; Simson and Weiss,
1988 ; Pavcovich and Ramirez, 1991 ) and the expression of tyrosine
hydroxylase, the rate-limiting enzyme for norepinephrine biosynthesis
(Thoenen, 1970 ; Zigmond et al., 1974 ; Richard et al., 1988 ; Smith et
al., 1991 ; Melia et al., 1992 ). In addition, it has been shown that
chronic stress increases the levels of adenylyl cyclase and protein
kinase A in this brain region, adaptations indicative of an
upregulation of the cAMP pathway (Melia et al., 1992 ). Results from the
current study demonstrate an additional adaptation to stress that could
contribute further to the upregulated cAMP pathway in the LC. Thus, the
chronic stress-induced increase in the levels of RGS4 expression in
this brain region would be expected to promote cAMP formation by
enhancing the inhibitory effect of RGS4 on G i and thereby reducing
the inhibitory effect of this G-protein on adenylyl cyclase. It should
also be mentioned that RGS4 seems to be expressed at particularly high
levels in the LC relative to that of other RGS proteins examined to
date (Gold et al., 1997 ).
Consistent with this hypothesis is the finding that RGS4 can exert a
negative modulatory effect on G i function in vitro (Huang et al., 1997 ). However, the G-protein subunit(s) regulated by this
RGS protein in the brain in vivo remains unclear, because in vitro studies indicate that RGS4 can also regulate
G q (Hepler et al., 1997 ; Huang et al., 1997 ). This latter finding
raises the interesting possibility that the stress- and
glucocorticoid-induced upregulation of RGS4 in the LC might influence
G q-mediated signaling cascades, in addition to the cAMP pathway, in
this brain region.
It has been shown that during chronic stress the LC is exposed to
increased levels of both CRF and glucocorticoids (Chappell et al.,
1986 ). Although the effect of CRF on RGS4 expression in the LC in
vivo remains unknown, our studies in the LC-like CATH.a cell line
showed that CRF has an opposing effect on RGS4 mRNA levels compared
with that of dexamethasone. If the same holds true in vivo,
these opposing effects may account for the smaller change in RGS4
expression seen in the LC after chronic stress compared with that seen
after acute or chronic corticosterone treatment alone.
In contrast to the upregulation of RGS4 expression observed in the LC,
chronic stress and corticosterone treatments were found to downregulate
levels of RGS4 mRNA in the PVN and pituitary, two components of the HPA
axis. This downregulation of RGS4 expression could lead to a
downregulation of the cAMP pathway in the PVN and pituitary, which
could contribute to glucocorticoid-induced negative feedback on these
tissues. It has been well documented that glucocorticoids exert a
profound negative feedback on the PVN and pituitary. Part of this
negative control is accomplished by inhibiting CRF and ACTH synthesis
and release from the PVN and pituitary, respectively. The synthesis and
release of CRF and ACTH are promoted by activation of the cAMP pathway
(Giguere et al., 1982 ; Labrie et al., 1982 ; Keller and Dallman, 1984 ;
Litvin et al., 1984 ; Dorin et al., 1993 ). Moreover, both CRF and ACTH act by stimulating adenylyl cyclase. Thus, the stress- and
glucocorticoid-induced downregulation of RGS4 expression in the PVN and
pituitary, via reduced inhibitory influence of G i function, would be
expected to attenuate the formation of cAMP in these tissues and could be part of the mechanism underlying negative feedback in the HPA axis.
In addition to studying the LC and PVN, we also examined regulation of
RGS4 mRNA levels in other brain regions, including the cerebral cortex
and hippocampus. A previous study reported differential regulation of
CRF receptor type 1 (CRFR1) mRNA in the frontal cortex and hippocampus
by chronic stress or corticosterone treatments (Iredale et al., 1996 ).
Expression of CRFR1 mRNA was decreased in the frontal cortex but
increased in the hippocampus by chronic unpredictable stress. Chronic
corticosterone administration did not affect receptor expression in
either region. The results reported here in general show no dramatic
effect of chronic stress or corticosterone treatments on RGS4
expression in the cortex and hippocampus, with the exception of a trend
for a slight decrease in the cingulate cortex with chronic
corticosterone exposure. However, it should be emphasized that these
negative conclusions are based solely on the use of in situ
hybridization, which can lead to false-negative results particularly in
the analysis of large brain structures (e.g., see Hayward et al.,
1990 ).
Dexamethasone induced a dose-dependent increase in RGS4 mRNA levels in
CATH.a cells and a dose-dependent decrease in AtT20 cells. The results
in AtT20 cells are consistent with data from a previous study, in which
dexamethasone treatment caused a dose- and time-dependent decrease in
CRFR1 mRNA in these cells (Iredale and Duman, 1997 ). The decreases in
RGS4 and CRFR1 expression could act in concert to produce a
downregulation of the cAMP pathway. In both cell lines, the effect of
dexamethasone took place between 1 and 2 hr; experiments with shorter
time points are needed to determine whether the effects may occur even
earlier. Results from the mRNA stability studies suggest that the
regulation of RGS4 mRNA by dexamethasone in CATH.a and AtT20 cells
occurs, at least in part, via changes in the stability of the mRNA.
However, this finding does not eliminate the possibility that
dexamethasone may also regulate RGS4 expression via additional
mechanisms, for example, via altered rates of transcription of the RGS4 gene.
Results of the present study demonstrate changes in RGS4 mRNA levels in
specific regions of the rat brain in response to chronic stress and
glucocorticoid treatments. A critical question is whether equivalent
changes occur in RGS4 protein levels; however this must await the
availability of suitable antibodies directed at this protein.
Nevertheless, the region-specific regulation of RGS4 expression seen in
the LC and HPA axis could contribute to the complex types of
adaptations (or maladaptations) that occur in the brain and could
mediate long-term plasticity to prolonged periods of stress.
 |
FOOTNOTES |
Received Nov. 3, 1998; revised Feb. 1, 1999; accepted Feb. 10, 1999.
This work was supported by grants from the National Institute of Mental
Health and the National Institute on Drug Abuse and by the Abraham
Ribicoff Research Facilities of the Connecticut Mental Health Center,
State of Connecticut Department of Mental Health and Addiction
Services. We wish to thank Dr. J. P. Herman for suggestions on the
pituitary in situ hybridization experiments, Dr. Y. Lee
for helpful discussions throughout the course of this study, Dr. M. Charlton for providing U373 astrocytoma cell mRNA, and Ms. J. J. Spencer for technical help with the chronic unpredictable stress experiments.
Correspondence should be addressed to Dr. Eric J. Nestler, Department
of Psychiatry, Yale University School of Medicine, 34 Park Street, New
Haven, CT 06508.
Dr. Iredale's present address: Central Research Division, Pfizer,
Eastern Point Road, Groton, CT 06340.
 |
REFERENCES |
-
Abercrombie ED,
Jacobs BL
(1987)
Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats. I. Acutely presented stressful and nonstressful stimuli.
J Neurosci
7:2837-2843[Abstract].
-
Battaglia G,
Webster EL,
De Souza EB
(1987)
Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system.
Synapse
1:572-581[Web of Science][Medline].
-
Berman DM,
Wilkie TM,
Gilman AG
(1996)
GAIP and RGS4 are GTPase-activating proteins for the Gi subfamily of G protein alpha subunits.
Cell
86:445-452[Web of Science][Medline].
-
Burchett SA,
Volk ML,
Bannon MJ,
Granneman JG
(1998)
Regulators of G protein signaling: rapid changes in mRNA abundance in response to amphetamine.
J Neurochem
70:2216-2219[Web of Science][Medline].
-
Chappell PB,
Smith MA,
Kilts CD,
Bissette G,
Ritchie J,
Anderson C,
Nemeroff CB
(1986)
Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress.
J Neurosci
6:2908-2914[Abstract].
-
Dorin RI,
Zlock DW,
Kilpatrick K
(1993)
Transcriptional regulation of human corticotropin releasing factor gene expression by cyclic adenosine 3',5'-monophosphate: differential effects at proximal and distal promoter elements.
Mol Cell Endocrinol
96:99-111[Web of Science][Medline].
-
Gall C,
Lauterborn J,
Guthrie K
(1995)
In situ hybridization: a sensitive measure of activity-dependent changes in neuronal gene expression.
In: Autoradiography and correlative imaging (Stumpf WE,
Solomon HF,
eds), pp 379-399. San Diego: Academic.
-
Giguere V,
Labrie F,
Cote J,
Coy DH,
Sueiras DJ,
Schally AV
(1982)
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action.
Proc Natl Acad Sci USA
79:3466-3469[Abstract/Free Full Text].
-
Gold SJ,
Ni YG,
Dohlman HG,
Nestler EJ
(1997)
Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain.
J Neurosci
17:8024-8037[Abstract/Free Full Text].
-
Hayward MD,
Duman RS,
Nestler EJ
(1990)
Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of rat brain.
Brain Res
525:256-266[Web of Science][Medline].
-
Hepler JR,
Berman DM,
Gilman AG,
Kozasa T
(1997)
RGS4 and GAIP are GTPase-activating proteins for Gq alpha and block activation of phospholipase C beta by gamma-thio-GTP-Gq alpha.
Proc Natl Acad Sci USA
94:428-432[Abstract/Free Full Text].
-
Huang C,
Hepler JR,
Gilman AG,
Mumby SM
(1997)
Attenuation of Gi- and Gq-mediated signaling by expression of RGS4 or GAIP in mammalian cells.
Proc Natl Acad Sci USA
94:6159-6163[Abstract/Free Full Text].
-
Hunt TW,
Fields TA,
Casey PJ,
Peralta EG
(1996)
RGS10 is a selective activator of G alpha i GTPase activity.
Nature
383:175-177[Medline].
-
Iredale PA,
Duman RS
(1997)
Glucocorticoid regulation of corticotropin-releasing factor1 receptor expression in pituitary-derived AtT-20 cells.
Mol Pharmacol
51:794-799[Abstract/Free Full Text].
-
Iredale PA,
Terwilliger R,
Widnell KL,
Nestler EJ,
Duman RS
(1996)
Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
Mol Pharmacol
50:1103-1110[Abstract].
-
Keller WM,
Dallman MF
(1984)
Corticosteroid inhibition of ACTH secretion.
Endocr Rev
5:1-24[Abstract/Free Full Text].
-
Koelle MR,
Horvitz HR
(1996)
EGL-10 regulates G protein signaling in the C. elegans nervous system and shares a conserved domain with many mammalian proteins.
Cell
84:115-125[Web of Science][Medline].
-
Labrie F,
Gagne B,
Lefevre G
(1982)
Corticotropin-releasing factor stimulates adenylate cyclase activity in the anterior pituitary gland.
Life Sci
31:1117-1121[Web of Science][Medline].
-
Litvin Y,
PasMantier R,
Fleischer N,
Erlichman J
(1984)
Hormonal activation of the cAMP-dependent protein kinases in AtT20 cells. Preferential activation of protein kinase I by corticotropin releasing factor, isoproterenol, and forskolin.
J Biol Chem
259:10296-10302[Abstract/Free Full Text].
-
Melia KR,
Rasmussen K,
Terwilliger RZ,
Haycock JW,
Nestler EJ,
Duman RS
(1992)
Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments.
J Neurochem
58:494-502[Web of Science][Medline].
-
Ortiz J,
DeCaprio JL,
Kosten TA,
Nestler EJ
(1995)
Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and glucocorticoid receptor in the ventral tegmental area.
Neuroscience
67:383-397[Web of Science][Medline].
-
Ortiz J,
Fitzgerald LW,
Lane S,
Terwilliger R,
Nestler EJ
(1996)
Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress.
Neuropsychopharmacology
14:443-452[Web of Science][Medline].
-
Pavcovich LA,
Ramirez OA
(1991)
Time course effects of uncontrollable stress in locus coeruleus neuronal activity.
Brain Res Bull
26:17-21[Web of Science][Medline].
-
Pavlides C,
Watanabe Y,
McEwen BS
(1993)
Effects of glucocorticoids on hippocampal long-term potentiation.
Hippocampus
3:183-192[Web of Science][Medline].
-
Paxinos G,
Watson C
(1982)
In: The rat brain in stereotaxic coordinates. New York: Academic.
-
Richard F,
Faucon BN,
Labatut R,
Rollet D,
Mallet J,
Buda M
(1988)
Modulation of tyrosine hydroxylase gene expression in rat brain and adrenals by exposure to cold.
J Neurosci Res
20:32-37[Web of Science][Medline].
-
Simson PE,
Weiss JM
(1988)
Altered activity of the locus coeruleus in an animal model of depression.
Neuropsychopharmacology
1:287-295[Web of Science][Medline].
-
Smith MA,
Brady LS,
Glowa J,
Gold PW,
Herkenham M
(1991)
Effects of stress and adrenalectomy on tyrosine hydroxylase mRNA levels in the locus coeruleus by in situ hybridization.
Brain Res
544:26-32[Web of Science][Medline].
-
Suri C,
Fung BP,
Tischler AS,
Chikaraishi DM
(1993)
Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice.
J Neurosci
13:1280-1291[Abstract].
-
Tesmer JJ,
Berman DM,
Gilman AG,
Sprang SR
(1997)
Structure of RGS4 bound to AlF4
-activated G(i alpha1): stabilization of the transition state for GTP hydrolysis.
Cell
89:251-261[Web of Science][Medline]. -
Thoenen H
(1970)
Induction of tyrosine hydroxylase in peripheral and central adrenergic neurones by cold-exposure of rats.
Nature
228:861-862[Web of Science][Medline].
-
Vaidya VA,
Marek GJ,
Aghajanian GK,
Duman RS
(1997)
5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.
J Neurosci
17:2785-2795[Abstract/Free Full Text].
-
Watson N,
Linder ME,
Druey KM,
Kehrl JH,
Blumer KJ
(1996)
RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits.
Nature
383:172-175[Medline].
-
Widnell KL,
Russell DS,
Nestler EJ
(1994)
Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro.
Proc Natl Acad Sci USA
91:10947-10951[Abstract/Free Full Text].
-
Wieland T,
Chen CK,
Simon MI
(1997)
The retinal specific protein RGS-r competes with the gamma subunit of cGMP phosphodiesterase for the alpha subunit of transducin and facilitates signal termination.
J Biol Chem
272:8853-8856[Abstract/Free Full Text].
-
Zigmond RE,
Schon F,
Iversen LL
(1974)
Increased tyrosine hydroxylase activity in the locus coeruleus of rat brain stem after reserpine treatment and cold stress.
Brain Res
70:547-552[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19103674-07$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
A. B. Hains and A. F.T. Arnsten
Molecular mechanisms of stress-induced prefrontal cortical impairment: Implications for mental illness
Learn. Mem.,
August 6, 2008;
15(8):
551 - 564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. B. Penn and J. L. Benovic
Regulation of Heterotrimeric G Protein Signaling in Airway Smooth Muscle
Proceedings of the ATS,
January 1, 2008;
5(1):
47 - 57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. V. Chowdari, M. Bamne, J. Wood, M. E. Talkowski, K. Mirnics, P. Levitt, D. A. Lewis, and V. L. Nimgaonkar
Linkage Disequilibrium Patterns and Functional Analysis of RGS4 Polymorphisms in Relation to Schizophrenia
Schizophr Bull,
January 1, 2008;
34(1):
118 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Jaen and C. A. Doupnik
RGS3 and RGS4 Differentially Associate with G Protein-coupled Receptor-Kir3 Channel Signaling Complexes Revealing Two Modes of RGS Modulation: PRECOUPLING AND COLLISION COUPLING
J. Biol. Chem.,
November 10, 2006;
281(45):
34549 - 34560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Traynor and R. R. Neubig
REGULATORs OF G PROTEIN SIGNALING & DRUGS OF ABUSE
Mol. Interv.,
February 1, 2005;
5(1):
30 - 41.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Clark and J. R. Traynor
Endogenous Regulator of G Protein Signaling Proteins Reduce {micro}-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells
J. Pharmacol. Exp. Ther.,
February 1, 2005;
312(2):
809 - 815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Grillet, V. Dubreuil, H. D. Dufour, and J.-F. Brunet
Dynamic Expression of RGS4 in the Developing Nervous System and Regulation by the Neural Type-Specific Transcription Factor Phox2b
J. Neurosci.,
November 19, 2003;
23(33):
10613 - 10621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Kramer, W. J. Cook, F. P. Roth, J. Zhu, H. Holman, D. M. Knipe, and D. M. Coen
Latent Herpes Simplex Virus Infection of Sensory Neurons Alters Neuronal Gene Expression
J. Virol.,
September 1, 2003;
77(17):
9533 - 9541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hollinger and J. R. Hepler
Cellular Regulation of RGS Proteins: Modulators and Integrators of G Protein Signaling
Pharmacol. Rev.,
September 1, 2002;
54(3):
527 - 559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. V. Chowdari, K. Mirnics, P. Semwal, J. Wood, E. Lawrence, T. Bhatia, S. N. Deshpande, T. B.K., R. E. Ferrell, F. A. Middleton, et al.
Association and linkage analyses of RGS4 polymorphisms in schizophrenia
Hum. Mol. Genet.,
June 1, 2002;
11(12):
1373 - 1380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. J. G. Karten, S. M. Nair, L. van Essen, R. Sibug, and M. Joels
Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons
PNAS,
November 9, 1999;
96(23):
13456 - 13461.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|